Immune-matched pipeline Leverage ISCO's parthenogenetic hpSC bank (UniStemCell) to position as a ready-to-serve source of immune-matched stem cells for regenerative therapies, enabling partnerships that reduce time-to-treatment for eye, nervous system, and liver diseases.

Strategic partnerships Target collaborations with Lifeline Cell Technology and Lifeline Skin Care to expand distribution, lab services, and consumer-facing products, creating cross-sell opportunities for research reagents, skin care, and cell-based tools.

Small team agility With 11-50 employees, emphasize nimble, founder-led engagement for rapid pilots, high-touch BD outreach, and faster decision cycles to secure strategic agreements and licensing deals.

Economic footholds Position ISCO’s revenue range and recent funding as a signal of growth potential to investors and corporate partners, offering co-development, milestone-based licensing, and scalable manufacturing collaborations.

Clinical ecosystem fit Highlight the regulatory-ready potential of hpSC-based therapies for immune-compatible cell therapies in the eye, nervous system, and liver to align with medical centers, contract research organizations, and biopharma seeking innovative treatment modalities.